Navigation Links
Spear Pharmaceutical Inc.'s ANDA for Fluorouracil Cream 5%
Date:5/20/2008

NEW YORK, May 20 /PRNewswire/ -- Spear Pharmaceuticals, Inc. received FDA approval for, and began shipping, Fluorouracil Cream 5%, USP, a generic equivalent to Valeant's Efudex(R) Cream. On April 11, 2008, the FDA approved the ANDA (Abbreviated New Drug Application) based on Spear's 318 patient study proving bioequivalence to Efudex(R) for the precancerous Actinic Keratoses (AK) skin condition, the indication for which the product is overwhelmingly prescribed (approximately 98% of patients). The product is also useful in the treatment of superficial basal cell carcinoma (sBCC).

Since December 2004, Valeant Pharmaceuticals has taken action to make it far more difficult for any generic Efudex(R) product to gain FDA approval (Efudex(R) was first approved in 1970 and has been off patent for 20 years.) Specifically, Valeant filed in December, 2004 a Citizen Petition that delayed the approval of the Spear generic product from the industry average of 16.6 months to 39 months.

Following this 39-month review, on April 11, 2008 (the same day the Spear ANDA was approved) Dr. Janet Woodcock, Director of FDA's Center for Drug Evaluation and Research, notified Valeant in a detailed 11-page document that FDA had carefully considered its arguments, and decided to approve the Spear product, confirming that the Spear product is bioequivalent to Efudex(R) Cream. In explaining FDA's decision to approve, Dr. Woodcock writes " ... even when clinical trials are needed, it has not been the Agency's policy to require that bioequivalence be shown in every indication if drug release from the dosage form and appearance at the site or sites of activity has been demonstrated ... Therefore, if a study demonstrated efficacy for a topical 5-FU formulation to treat AK, this would provide assurance that the formulation would penetrate the skin sufficiently to treat sBCC." Dr. Woodcock further points out "The courts have expressly upheld FDA's regulatory implementation of the Act's bioequivalence requirements." Like thousands of generic drugs that have been approved over the years, the FDA approved the Spear product based on precedent and pursuant to its well established scientific, medical, and statistical review procedures for determining bioequivalence.

Despite this very clear position of the FDA, and the fact that the Courts do not overrule the FDA on matters of science, Valeant, in a further effort to block generic competition, sued the FDA asking the court to substitute its scientific judgment for that of the FDA.

Because of certain administrative issues regarding the FDA's record, Spear has voluntarily agreed not to ship additional product until the end of May, at which time we fully expect that the FDA will resolve its administrative issues and Spear shipments of Fluorouracil Cream will resume.

http://www.spearpharma.com

Stephen Basile

Senior Vice President, Sales and Marketing

Spear Pharmaceuticals, Inc.

973-895-6447 phone

basile@spearpharma.com


'/>"/>
SOURCE Spear Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Running Pioneer Kathrine Switzer Will Headline Women on the Move Conference August 13-15, 2008 in Spearfish, SD
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, and Dr. Barry Karlin, Nations #1 Drug Treatment Provider, to Spearhead Drug Treatment WVA Advocacy Day Feb 13-14; 142,000 Need, Dont Get Treatment in State
3. Britney Spears: Lets Talk About All of Us
4. Bellevue Dentist Gives a Thumbs Up to Britney Spears Smile
5. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
6. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
7. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
8. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
9. Genesis Pharmaceuticals Donates Medicine to China Sichuan Earthquake Relief
10. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
11. Jazz Pharmaceuticals to Present at Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: